指南与共识神经CTMR

ASFNR慢性硬膜下血肿影像实践声明

ASFNR Clinical State of Practice Statement on Imaging of Chronic Subdural Hematoma.
PubMed 文献 · AJNR Am J Neuroradiol · 2026-10-20

美国功能神经放射学会通过专家共识与文献回顾,针对慢性硬膜下血肿影像评估形成实践声明。声明强调平扫CT仍是主要评估手段,血肿负荷应以最大厚度、中线移位及容积描述。内部结构应按Nakaguchi分型报告,高级影像技术目前仅作为问题解决工具而非常规应用。

要点

  • 平扫CT是慢性硬膜下血肿评估的首选影像方式
  • 内部结构按Nakaguchi四型描述并报告混合或过渡特征
  • 高级影像技术目前仅用于问题解决而非常规评估

核心结论

  • 平扫CT仍是慢性硬膜下血肿评估的主要影像方式
  • 血肿负荷应以垂直于内板的最大厚度、中线移位及容积来表征
  • 内部结构应采用Nakaguchi分型框架描述,混合或过渡特征应明确报告
  • 高级影像技术目前仅具问题解决作用而非常规角色
  • 影像表型或高级影像生物标志物在指导治疗选择前需标准化报告和前瞻性验证

研究设计与样本

  • 由美国功能神经放射学会临床实践委员会通过专家共识和现有文献回顾制定
  • 为临床实践状态声明,非系统综述或随机对照研究

关键影像表现/征象

  • Nakaguchi分型将血肿内部结构分为均质型、分层型、分离型和小梁型
  • 不规则、新月形或多房分隔的积液可用分割法更准确计算容积
  • 容积可用ABC/2公式估算

诊断标准与关键数值

  • 血肿最大厚度应垂直于内板测量
  • 容积可用ABC/2公式估算,不规则、新月形或多房分隔者用分割法更准确
  • 内部结构分型采用Nakaguchi框架:均质型、分层型、分离型、小梁型
  • 混合或过渡特征应明确报告

临床应用与阅片要点

  • 报告中应常规描述血肿最大厚度、中线移位,适当时描述容积
  • 阅片时应按Nakaguchi分型描述血肿内部结构并明确报告混合或过渡特征
  • 双能CT、光子计数CT、MRI和动脉自旋标记可提供膜活动信息,但仅作问题解决工具使用
  • 影像表型尚未纳入随机试验或验证的治疗选择算法,不应单独用于指导治疗决策

局限性

  • 影像表型尚未纳入随机试验或经过验证的治疗选择算法
  • 高级影像技术证据有限,多为单中心研究
  • 标准化定义和报告仍然缺乏

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The efficacy of middle meningeal artery embolization (MMAE) for chronic subdural hematoma (cSDH) has heightened interest in imaging biomarkers that may reflect neomembrane activity, predict recurrence, and identify patients most likely to benefit from treatment. Characterization of hematoma internal architecture, referred to as the imaging phenotype, may provide indirect information regarding the biological activity and maturation of the neomembrane. However, imaging phenotype has not been incorporated into randomized trials or validated treatment-selection algorithms, and standardized definitions and reporting remain lacking.

METHODS: The American Society of Functional Neuroradiology Clinical Practice Committee developed this State of Practice statement through expert consensus and review of the available literature.

KEY MESSAGE: Noncontrast CT (NCCT) remains the primary imaging modality for cSDH assessment. Hematoma burden should be characterized by maximum thickness measured perpendicular to the inner table, midline shift, and, when appropriate, volume. Volume may be estimated using the ABC/2 formula, whereas segmentation is more accurate for irregular, crescentic, or multiloculated collections when available. Internal architecture should be described using the Nakaguchi framework of homogeneous, laminar, separated, and trabecular phenotypes, with mixed or transitional features explicitly reported. Advanced techniques, including dual-energy CT, photon-counting CT, MRI, and arterial spin labeling, may provide information regarding membrane activity but are supported by limited, largely single-center evidence and currently have a problem-solving rather than routine role. Standardized reporting and prospective validation are needed before imaging phenotype or advanced-imaging biomarkers can guide treatment selection.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Ahmed, Essibayi, Kakadiya, et al. ASFNR Clinical State of Practice Statement on Imaging of Chronic Subdural Hematoma. AJNR Am J Neuroradiol. 2026. PMID: 42901727. doi:10.3174/ajnr.A9690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。